Enhancing Antitumor Immunity in Lewis Lung Cancer Through Plasma-treated Medium-induced Activation of Dendritic Cells

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2024 Nov 23

PMID 39580412

Authors

Chae Bok Lee

Hei Gwon Choi

Sintayehu Kebede Gurmessa

In-Taek Jang

Naresh Kumar

Zongyou Jiang

Nagendra Kumar Kaushik

Hwa-Jung Kim

Affiliations

Soon will be listed here.

Abstract

Background: Recently, atmospheric non-thermal plasma jet-treated medium (PTM) has been recognized as a novel strategy in cancer therapy and lymphocyte activation. However, PTM has limitations in inducing a robust antitumor-immune response. This study demonstrated that PTM treatment inhibited tumor progression by activating dendritic cells (DCs).

Method: In this study, we investigated the effects of PTM on selective cytotoxicity and intracellular reactive oxygen species (ROS) generation and oxidative stress-mediated signaling (e.g., glutathione peroxidase, catalase) using respective fluorescence probes in Lewis lung cancer (LLC) cells. Then, the PTM affects the expression of interferon-gamma (IFN)-γ-induced programmed death-ligand 1 (PD-L1) and inhibition of signal transducer and activator of transcription 1 (STAT1) in LLC cells using immunoblotting. Additionally, PTM effects on the tumor cell's death and activation of DCs were done by co-culturing DCs with or without tumor cells. Further, a mouse model was used to evaluate the synergistic antitumor effects of PTM and DCs where tumors are grown under the skin.

Results: PTM-exposed tumor cells increase intracellular superoxide production, enhancing ROS generation and leading to cancer immunogenic cell death. In addition, PTM suppresses IFN-γ-induced PD-L1 expression and STAT1 activation in tumor cells. The activation of DCs induced by PTM is downregulated when these cells are co-cultured with tumor cells. In vivo, intraperitoneal injection of PTM-activated DCs, as a synergistic agent to intertumoral PTM treatment, led to increased CD4 and CD8 T cell infiltration into the tumor and spleen and eventually decreased tumor growth.

Conclusion: Overall, this research introduces a promising avenue for improving lung cancer treatment using PTM to stimulate an immune response and induce cell death in tumor cells. Further studies will be essential to validate these findings and explore clinical applications.

References

Tan Y, Leong C, Cheong S . Observation of dendritic cell morphology under light, phase-contrast or confocal laser scanning microscopy. Malays J Pathol. 2011; 32(2):97-102. View

Banchereau J, Steinman R . Dendritic cells and the control of immunity. Nature. 1998; 392(6673):245-52. DOI: 10.1038/32588. View

Garg A, Dudek-Peric A, Romano E, Agostinis P . Immunogenic cell death. Int J Dev Biol. 2015; 59(1-3):131-40. DOI: 10.1387/ijdb.150061pa. View

Schoenborn J, Wilson C . Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol. 2007; 96:41-101. DOI: 10.1016/S0065-2776(07)96002-2. View

Wu F, Fan J, He Y, Xiong A, Yu J, Li Y . Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer. Nat Commun. 2021; 12(1):2540. PMC: 8100173. DOI: 10.1038/s41467-021-22801-0. View

Chen Z, Fillmore C, Hammerman P, Kim C, Wong K . Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014; 14(8):535-46. PMC: 5712844. DOI: 10.1038/nrc3775. View

Fang T, Cao X, Shen B, Chen Z, Chen G . Injectable cold atmospheric plasma-activated immunotherapeutic hydrogel for enhanced cancer treatment. Biomaterials. 2023; 300:122189. DOI: 10.1016/j.biomaterials.2023.122189. View

Katopodi T, Petanidis S, Charalampidis C, Chatziprodromidou I, Eskitzis P, Tsavlis D . Tumor-Infiltrating Dendritic Cells: Decisive Roles in Cancer Immunosurveillance, Immunoediting, and Tumor T Cell Tolerance. Cells. 2022; 11(20). PMC: 9600942. DOI: 10.3390/cells11203183. View

Malla R, Surepalli N, Farran B, V Malhotra S, Nagaraju G . Reactive oxygen species (ROS): Critical roles in breast tumor microenvironment. Crit Rev Oncol Hematol. 2021; 160:103285. DOI: 10.1016/j.critrevonc.2021.103285. View

10.

Domagala-Kulawik J . The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention. Transl Lung Cancer Res. 2015; 4(2):177-90. PMC: 4384216. DOI: 10.3978/j.issn.2218-6751.2015.01.11. View

11.

Heirman P, Boxem W, Bogaerts A . Reactivity and stability of plasma-generated oxygen and nitrogen species in buffered water solution: a computational study. Phys Chem Chem Phys. 2019; 21(24):12881-12894. DOI: 10.1039/c9cp00647h. View

12.

Freund E, Liedtke K, van der Linde J, Metelmann H, Heidecke C, Partecke L . Physical plasma-treated saline promotes an immunogenic phenotype in CT26 colon cancer cells in vitro and in vivo. Sci Rep. 2019; 9(1):634. PMC: 6345938. DOI: 10.1038/s41598-018-37169-3. View

13.

Guleria A, Chandna S . ATM kinase: Much more than a DNA damage responsive protein. DNA Repair (Amst). 2016; 39:1-20. DOI: 10.1016/j.dnarep.2015.12.009. View

14.

Gardner A, Ruffell B . Dendritic Cells and Cancer Immunity. Trends Immunol. 2016; 37(12):855-865. PMC: 5135568. DOI: 10.1016/j.it.2016.09.006. View

15.

Yang H, Villani R, Wang H, Simpson M, Roberts M, Tang M . The role of cellular reactive oxygen species in cancer chemotherapy. J Exp Clin Cancer Res. 2018; 37(1):266. PMC: 6211502. DOI: 10.1186/s13046-018-0909-x. View

16.

Chio I, Tuveson D . ROS in Cancer: The Burning Question. Trends Mol Med. 2017; 23(5):411-429. PMC: 5462452. DOI: 10.1016/j.molmed.2017.03.004. View

17.

Nakamura H, Takada K . Reactive oxygen species in cancer: Current findings and future directions. Cancer Sci. 2021; 112(10):3945-3952. PMC: 8486193. DOI: 10.1111/cas.15068. View

18.

Azzariti A, Iacobazzi R, Di Fonte R, Porcelli L, Gristina R, Favia P . Plasma-activated medium triggers cell death and the presentation of immune activating danger signals in melanoma and pancreatic cancer cells. Sci Rep. 2019; 9(1):4099. PMC: 6411873. DOI: 10.1038/s41598-019-40637-z. View

19.

Sauter M, Sauter R, Nording H, Olbrich M, Emschermann F, Langer H . Protocol to isolate and analyze mouse bone marrow derived dendritic cells (BMDC). STAR Protoc. 2022; 3(3):101664. PMC: 9471451. DOI: 10.1016/j.xpro.2022.101664. View

20.

Svensson-Arvelund J, Cuadrado-Castano S, Pantsulaia G, Kim K, Aleynick M, Hammerich L . Expanding cross-presenting dendritic cells enhances oncolytic virotherapy and is critical for long-term anti-tumor immunity. Nat Commun. 2022; 13(1):7149. PMC: 9684150. DOI: 10.1038/s41467-022-34791-8. View